Apricus Bio to Float New Stock and Warrants

Apricus Biosciences (NASDAQ: APRI  ) is hoping to widen its capital base significantly. The company is floating a mix of common stock and warrants that it hopes will raise net proceeds of nearly $16 million. Six million shares will be sold in an underwritten public offering at $2.85 apiece, and 3 million warrants will be issued separately at an exercise price of $3.40 per share. 

Additionally, the company's underwriters have been granted a 30-day purchase option for up to an additional 900,000 shares and 450,000 warrants to cover over-allotments, if any. 

Apricus Bio said it plans to use the proceeds of the issue for capital expenditures, research and development activities, clinical trial costs, and "general corporate purposes."  

Lazard's Lazard Capital Markets is the sole book-running manager of the issue.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2451066, ~/Articles/ArticleHandler.aspx, 4/16/2014 6:45:49 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement